Retevmo (selpercatinib) / Pfizer, Eli Lilly, Innovent Biologics - LARVOL DELTA

Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431. (PubMed, J Thorac Oncol) - "In patients with advanced RET fusion-positive lung cancer treated in this global, multicenter trial, outcomes with first-line chemoimmunotherapy and chemotherapy were not significantly different in this secondary analysis. Using chemotherapy alone is a reasonable strategy for these oncogene-driven tumors. Based on the overall findings from LIBRETTO-431, selective RET inhibitors remain the preferred first-line therapy for patients with RET fusion-positive NSCLC."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1 • RET

Medullary thyroid carcinoma in clinical practice: a single-center retrospective study (ETA 2026) - "Two patients are under therapy with selpercatinib and 1 patient with vandetanib. MTC affected mostly middle-aged female patients and was hereditary in 26,9% of cases. Calcitonin was a reliable marker of MTC, unlike FNAC, which showed an inferior diagnostic yield. A significant rate of biochemical cure was attained post-operatively, while latest data showed an increase in locoregional and metastatic disease."

Retrospective data • Endocrine Disorders • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Updated Results of Randomized Phase 3 Study of Selpercatinib vs Cabozantinib or Vandetanib (C/V) in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer (MTC) (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Real-world outcomes of selpercatinib in RET fusion-positive NSCLC: a Colombian multicenter experience (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • RET

CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non-Small Cell Lung Cancer. (PubMed, J Clin Oncol) - "Serial CNS scans were studied from LIBRETTO-431, a randomized phase III trial of selpercatinib versus platinum/pemetrexed ± pembrolizumab whose primary results have been previously disclosed. These data demonstrate that selpercatinib effectively treats existing CNS disease and prevents or delays the formation of new CNS metastases. These results reinforce the importance of identifying RET fusions in first-line patients with NSCLC and treating with selpercatinib."

Journal • Metastases • CNS Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • RET

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. (PubMed, J Clin Oncol) - P1/2 | "At the data cutoff of January 2023, the objective response rate was 82.5% among patients with cabozantinib/vandetanib-naïve MTC and 95.8% among patients with treatment-naïve TC...The safety profile of selpercatinib was consistent with previous reports. With an additional follow-up of 37 months and 228 more patients from the last disclosure, selpercatinib continued to provide durable and robust responses in treatment-naïve and previously treated patients with RET-mutant MTC and RET fusion-positive TC."

Journal • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial. (ASCO 2026) - P3 | "Selpercatinib achieved a statistically significant and clinically meaningful improvement in event-free survival compared to placebo in patients with early-stage RET+ NSCLC. These data add to the body of evidence for targeted therapy, including EGFR and ALK inhibitors, in the adjuvant NSCLC setting and underscore the importance of comprehensive genomic testing at diagnosis of NSCLC across disease stages to inform optimal therapeutic decision-making."

Clinical • Late-breaking abstract • P3 data • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • RET

Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma. (PubMed, J Clin Endocrinol Metab) - P1/2 | "These data support selpercatinib as an effective therapy against RET-mutant pheochromocytoma, adding to the diversity of RET-activated tumor types that may benefit from targeted RET inhibition."

Journal • Endocrine Cancer • Oncology • Solid Tumor • RET

Impact of Neoadjuvant TKI Therapy on Tumor Reduction and Resectability in Locally Advanced Thyroid Carcinoma (ETA 2026) - "Therapies included selective (dabrafenib/trametinib, entrectinib, larotrectinib, selpercatinib) and multikinase inhibitors (lenvatinib, cabozantinib, vandetanib)... Neoadjuvant TKI therapy demonstrated promising results in locally advanced thyroid carcinoma, achieving high disease control rates and enabling surgical resection in over one-third of cases. Outcomes were comparable between selective and multikinase TKIs, and meaningful responses were observed across histological subtypes, although survival remained significantly longer in differentiated tumors. These findings, representing one of the largest single-center cohorts, reinforce the growing role of neoadjuvant therapy in multidisciplinary management of advanced thyroid cancer."

Clinical • Metastases • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial. (PubMed, ESMO Open) - "A majority of patients with RET-driven cancers improved or remained stable on most QLQ-C30 domains, demonstrating favorable health-related quality of life as measured by the QLQ-C30 during long-term treatment with selpercatinib."

Journal • P1/2 data • Patient reported outcomes • Endocrine Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

How to manage radioiodine-refractory thyroid cancer in the era of precision medicine. (PubMed, Drugs Context) - "Three multi-kinase inhibitors have been approved for this indication: lenvatinib and sorafenib as a first-line option and cabozantinib as a second-line option...Thus, additional selective inhibitors have been approved: larotrectinib and entrectinib for NTRK + tumours, selpercatinib and pralsetinib for RET + tumours, and crizotinib, alectinib and lorlatinib for ALK + tumours. Such a personalized approach increases clinical benefit whilst minimizing adverse events. Future studies should focus on the combination of tyrosine kinase inhibitors and immune-checkpoint inhibitors; currently, there is no strong evidence that redifferentiation strategies add clinical benefit in terms of overall survival or progression-free survival."

Journal • Review • Oncology • Solid Tumor • Thyroid Gland Carcinoma • ALK • NTRK

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. (PubMed, N Engl J Med) - P1/2 | "Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.)."

Clinical • Journal • Cardiovascular • Heart Failure • Hypertension • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Clinical Impact Associated With Dose Reductions of Selpercatinib and Pralsetinib in Advanced RET-rearranged NSCLC (IASLC-WCLC 2026) - "Conclusions : Dose reduction of selective RET inhibitors was not associated with inferior real-world PFS or TTNT, nor with increased rates of intracranial progression. These findings suggest that improving treatment tolerability through dose modification does not compromise clinical outcomes, although larger studies are needed to confirm these observations."

Clinical • Metastases • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

First-Line Chemoimmunotherapy and Chemotherapy Outcomes in RET Fusion-Positive Lung Cancer Patients in LIBRETTO-431 (IASLC-WCLC 2026) - "Methods : In the registrational, phase 3 LIBRETTO-431 study, RET fusion-positive lung cancer patients were randomized to selpercatinib or platinum doublet chemotherapy (carboplatin/cisplatin and pemetrexed), with or without pembrolizumab. Conclusions : In advanced RET fusion-positive lung cancers treated in this global, multicenter trial, outcomes with first-line chemoimmunotherapy and chemotherapy were not different. Using chemotherapy alone is a reasonable strategy for these oncogene-driven tumors."

Clinical • Lung Cancer • Oncology • Solid Tumor • PD-L1 • RET

RET Fusion in Solid Tumors (IASLC-WCLC 2026) - "No statistically significant differences in mPFS were detected between selpercatinib, pralsetinib, and other RET-TKIs (13 vs. 12 vs. 10 months; P=0.37), nor between first-line and subsequent-line administration (12 vs. 13 months, P=0.91). Co-occurring driver gene alterations predicted poorer outcomes. RET-TKIs were generally well tolerated with distinct safety profiles."

Hypertension • Infectious Disease • Lung Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • KIF5B • RET • TP53

Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: A global, multicenter, registrational trial update (LIBRETTO-001). (ASCO 2022) - P1/2 | "Selpercatinib continued to demonstrate durable antitumor activity in pts with RET fusion+ cancers across multiple tumor types. No new safety signals were identified. These results emphasize the importance of comprehensive genomic profiling to identify actionable oncogenic drivers, including RET fusions."

Clinical • Pan tumor • Biliary Cancer • Breast Cancer • Carcinoid Tumor • Cholangiocarcinoma • Endocrine Cancer • Gastrointestinal Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Sarcoma • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Highly selective RET inhibitor selpercatinib preserves skeletal muscle in patients with advanced medullary thyroid carcinoma. (ETA 2026) - "The findings of this study suggest that selpercatinib preserves skeletal muscle to a greater extent than other anticancer therapies. Maintenance of skeletal muscle mass is metabolically relevant and may help sustain functional capacity and performance status in patients with advanced disease undergoing long-term targeted treatment."

Clinical • Metastases • Cachexia • Oncology • Sarcopenia • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma

Tissue-Agnostic Cancer Therapy Approvals. (PubMed, Hematol Oncol Clin North Am) - "In stark contrast to conventional cancer treatments that categorize malignancies based on their tissue of origin (eg, breast, lung, renal cell, etc), tumor-agnostic therapies transcend histologic boundaries, honing in on the genetic and molecular attributes of tumors, regardless of their location. This article offers a comprehensive review of the current landscape of tissue-agnostic cancer therapies and provides clinical insights to empower surgical oncologists with a deeper understanding of these innovative therapeutic approaches."

Journal • Review • Oncology • Renal Cell Carcinoma

Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch. (PubMed, NPJ Precis Oncol) - P1/2 | "In conclusion, the standard readings from commercially available wearable devices can be useful for the monitoring of treatment response to targeted therapy and may serve as digital biomarkers in clinical trials. This approach marks a significant advancement in patient-centric healthcare, leveraging technology to enhance the effectiveness and precision of treatment evaluation."

Journal • Endocrine Cancer • Gastrointestinal Cancer • Hepatology • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • CCDC6 • RET

Treatment patterns and outcomes for patients with RET-altered thyroid cancer treated with selpercatinib in Europe: Final Results from the SPRINT-RET study. (ETA 2026) - "Results confirm the real-world effectiveness of selpercatinib in treating RET -mutated MTC, demonstrating robust disease control and PFS. Findings in RET fusion-positive nMTC are from a small sample and should be interpreted cautiously. Overall, these findings reinforce the importance of genomic testing to identify RET alterations in patients with TC, and treatment with selpercatinib in this population."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • RET

Management of ectopic Cushing syndrome in medullary thyroid carcinoma: from case reports to systematic literature review. (PubMed, Front Endocrinol (Lausanne)) - "Selective RET inhibitors, particularly selpercatinib, have recently emerged as a promising treatment option, with all five reported cases demonstrating rapid biochemical improvement and radiologic responses...Two cases received vandetanib producing favorable biochemical (calcitonin) and radiologic responses...Emerging data suggests that selective RET inhibitors may lead to simultaneous control of both tumor progression and cortisol excess in RET-mutated disease, although current data remain limited to case reports. The four institutional cases offer additional real-world clinical context and are presented separately from the systematic review to maintain methodological rigor."

Journal • Review • Cushing’s Disease • Endocrine Disorders • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Medullary Carcinoma • RET

Retevmo (selpercatinib), Korea’s only selective RET inhibitor, has reportedly cleared price negotiations for national health insurance coverage, paving the way for potential reimbursement in October. (Korea Biomedical Review) - "The proposed coverage applies to adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer and to adults and pediatric patients aged 12 or older with advanced or metastatic RET-mutant medullary thyroid cancer requiring systemic therapy."

Reimbursement • Non Small Cell Lung Cancer

Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001. (ASCO-GI 2024) - P1/2 | "Selpercatinib continued to demonstrate durable antitumor activity and tolerable safety in pts with RET fusion+ cancers across multiple tumor types and fusion partners, including difficult-to-treat GI cancers with poor results in standard-of-care options, such as pancreatic and colorectal. These results emphasize the importance of comprehensive genomic profiling across all tumor types in order to identify actionable oncogenic drivers, including RET fusions. Clinical trial information: NCT03157128."

Clinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • RET

Efficacy and Safety of Adjuvant Selpercatinib in Patients With RET+ NSCLC: China Subpopulation Results From LIBRETTO-432 (IASLC-WCLC 2026) - P3 | "Adverse events with selpercatinib in this subpopulation were comparable to those reported in metastatic RET + NSCLC. Conclusions : Efficacy outcomes in the Chinese subpopulation from LIBRETTO-432 were generally consistent with those in the global PAS and ITT populations, and the safety profile of selpercatinib was consistent with the global study population."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • RET

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. (PubMed, Lancet Oncol) - P1/2 | "Selpercatinib showed clinically meaningful activity in the RET fusion-positive tumour-agnostic population, with a safety profile consistent with that observed in other indications. Comprehensive genomic testing that includes RET fusions will be crucial for identifying patients who might benefit from selpercatinib."

Journal • P1/2 data • Pan tumor • Cardiovascular • Endocrine Cancer • Hypertension • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma • RET